<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35494424</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>03</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Print">2352-5517</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>30</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
            </PubDate>
          </JournalIssue>
          <Title>Practical laboratory medicine</Title>
          <ISOAbbreviation>Pract Lab Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Improving acute kidney injury diagnostic precision using biomarkers.</ArticleTitle>
        <Pagination>
          <StartPage>e00272</StartPage>
          <MedlinePgn>e00272</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">e00272</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.plabm.2022.e00272</ELocationID>
        <Abstract>
          <AbstractText>Acute kidney injury (AKI) is common in hospitalized patients of all ages and is associated with significant morbidity and mortality. Accurate prediction and early identification of AKI is of utmost importance because no therapy exists to mitigate AKI once it has occurred. Yet, serum creatinine lacks adequate sensitivity and specificity, and quantification of urine output is challenging in incontinent children without indwelling bladder catheters. Integration of clinically available biomarkers have the potential to delineate unique AKI phenotypes that could have important prognostic and therapeutic implications. Plasma Cystatin C, urine neutrophil gelatinase associated lipocalin (NGAL) and the urinary product of tissue inhibitor metalloproteinase (TIMP-2) and insulin growth factor binding protein-7 (IGFBP7) are clinically available. These biomarkers have been studied in heterogenous populations across the age spectrum and in a variety of clinical settings for prediction of AKI. The purpose of this review is to describe and discuss the clinically available AKI biomarkers including how they have been used to delineate AKI phenotypes.</AbstractText>
          <CopyrightInformation>© 2022 The Authors.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Hasson</LastName>
            <ForeName>Denise</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati School of Medicine, Cincinnati, OH, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Menon</LastName>
            <ForeName>Shina</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, Seattle Children's Hospital, University of Washington School of Medicine, Seattle, WA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gist</LastName>
            <ForeName>Katja M</ForeName>
            <Initials>KM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati School of Medicine, Cincinnati, OH, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>09</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Pract Lab Med</MedlineTA>
        <NlmUniqueID>101690848</NlmUniqueID>
        <ISSNLinking>2352-5517</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Acute kidney injury</Keyword>
        <Keyword MajorTopicYN="N">Biomarkers</Keyword>
        <Keyword MajorTopicYN="N">Phenotype</Keyword>
        <Keyword MajorTopicYN="N">Precision medicine</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>31</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35494424</ArticleId>
        <ArticleId IdType="pmc">PMC9046880</ArticleId>
        <ArticleId IdType="doi">10.1016/j.plabm.2022.e00272</ArticleId>
        <ArticleId IdType="pii">S2352-5517(22)00011-7</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Kaddourah A., Basu R.K., Bagshaw S.M., Goldstein S.L., Investigators A. Epidemiology of acute kidney injury in critically ill children and young adults. N. Engl. J. Med. 2017;376(1):11–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5322803</ArticleId>
            <ArticleId IdType="pubmed">27959707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rewa O., Bagshaw S.M. Acute kidney injury-epidemiology, outcomes and economics. Nat. Rev. Nephrol. 2014;10(4):193–207.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24445744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jetton J.G., Boohaker L.J., Sethi S.K., Wazir S., Rohatgi S., Soranno D.E., Chishti A.S., Woroniecki R., Mammen C., Swanson J.R., Sridhar S., Wong C.S., Kupferman J.C., Griffin R.L., Askenazi D.J., Neonatal Kidney C. Incidence and outcomes of neonatal acute kidney injury (AWAKEN): a multicentre, multinational, observational cohort study. Lancet Child Adolesc. Health. 2017;1(3):184–194.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5933049</ArticleId>
            <ArticleId IdType="pubmed">29732396</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alten J.A., Cooper D.S., Blinder J.J., Selewski D.T., Tabbutt S., Sasaki J., Gaies M.G., Bertrandt R.A., Smith A.H., Reichle G., Gist K.M., Banerjee M., Zhang W., Hock K.M., Borasino S., Neonatal, Pediatric H., Renal Outcomes Network I. Epidemiology of acute kidney injury after neonatal cardiac surgery: a report from the multicenter neonatal and pediatric heart and renal outcomes network. Crit. Care Med. 2021;49(10):e941–e951.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34166288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Griffin B.R., You Z., Holmen J., SooHoo M., Gist K.M., Colbert J.F., Chonchol M., Faubel S., Jovanovich A. Incident infection following acute kidney injury with recovery to baseline creatinine: a propensity score matched analysis. PLoS One. 2019;14(6)</Citation>
        </Reference>
        <Reference>
          <Citation>Menon S., Kirkendall E.S., Nguyen H., Goldstein S.L. Acute kidney injury associated with high nephrotoxic medication exposure leads to chronic kidney disease after 6 months. J. Pediatr. 2014;165(3):522–527 e2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24928698</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gameiro J., Marques F., Lopes J.A. Long-term consequences of acute kidney injury: a narrative review. Clin. Kidney J. 2021;14(3):789–804.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7986368</ArticleId>
            <ArticleId IdType="pubmed">33777362</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tanaka S., Okusa M.D. Crosstalk between the nervous system and the kidney. Kidney Int. 2020;97(3):466–476.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7039752</ArticleId>
            <ArticleId IdType="pubmed">32001065</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Benoit S.W., Devarajan P. Acute kidney injury: emerging pharmacotherapies in current clinical trials. Pediatr. Nephrol. 2018;33(5):779–787.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5723563</ArticleId>
            <ArticleId IdType="pubmed">28601936</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faubel S., Chawla L.S., Chertow G.M., Goldstein S.L., Jaber B.L., Liu K.D. N. Acute kidney injury advisory group of the American society of, ongoing clinical trials in AKI. Clin. J. Am. Soc. Nephrol. : CJASN. 2012;7(5):861–873.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22442183</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kellum J.A., Lameire N., Group K.A.G.W. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1) Crit. Care. 2013;17(1):204.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4057151</ArticleId>
            <ArticleId IdType="pubmed">23394211</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Selewski D.T., Charlton J.R., Jetton J.G., Guillet R., Mhanna M.J., Askenazi D.J., Kent A.L. Neonatal acute kidney injury. Pediatrics. 2015;136(2):e463–e473.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26169430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin J., Fernandez H., Shashaty M.G., Negoianu D., Testani J.M., Berns J.S., Parikh C.R., Wilson F.P. False-positive rate of AKI using consensus creatinine-based criteria. Clin. J. Am. Soc. Nephrol. 2015;10(10):1723–1731.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4594067</ArticleId>
            <ArticleId IdType="pubmed">26336912</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu X., Nie S., Zhang A., Jianhua M., Liu H.P., Xia H., Xu H., Liu Z., Feng S., Zhou W., Liu X., Yang Y., Tao Y., Feng Y., Chen C., Wang M., Zha Y., Feng J.H., Li Q., Ge S., Chen J., He Y., Teng S., Hao C., Liu B.C., Tang Y., Wang L.J., Qi J.L., He W., He P., Liu Y., Hou F.F. A new criterion for pediatric AKI based on the reference change value of serum creatinine. J. Am. Soc. Nephrol. 2018;29(9):2432–2442.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6115652</ArticleId>
            <ArticleId IdType="pubmed">30054338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chawla L.S., Davison D.L., Brasha-Mitchell E., Koyner J.L., Arthur J.M., Shaw A.D., Tumlin J.A., Trevino S.A., Kimmel P.L., Seneff M.G. Development and standardization of a furosemide stress test to predict the severity of acute kidney injury. Crit. Care. 2013;17(5):R207.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4057505</ArticleId>
            <ArticleId IdType="pubmed">24053972</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Penk J., Gist K.M., Wald E.L., Kitzmiller L., Webb T.N., Li Y., Cooper D.S., Goldstein S.L., Basu R.K. Furosemide response predicts acute kidney injury in children after cardiac surgery. J. Thorac. Cardiovasc. Surg. 2019;157(6):2444–2451. doi: 10.1016/j.jtcvs.2018.12.076.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jtcvs.2018.12.076</ArticleId>
            <ArticleId IdType="pubmed">30745052</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kakajiwala A., Kim J.Y., Hughes J.Z., Costarino A., Ferguson J., Gaynor J.W., Furth S.L., Blinder J.J. Lack of furosemide responsiveness predicts acute kidney injury in infants after cardiac surgery. Ann. Thorac. Surg. 2017;104(4):1388–1394.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28499652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gist K.M., Penk J., Wald E., Kitzmiller L., Webb T.N., Brinton J.T., Soranno D.E., Goldstein S.L., Basu R.J. Urine quantification following furosemide for severe acute kidney injury prediction in critically ill children. J. Pediatr. Intensive Care. 2021;(03) doi: 10.1055/s-0041-1732447.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1055/s-0041-1732447</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koyner J.L., Davison D.L., Brasha-Mitchell E., Chalikonda D.M., Arthur J.M., Shaw A.D., Tumlin J.A., Trevino S.A., Bennett M.R., Kimmel P.L., Seneff M.G., Chawla L.S. Furosemide stress test and biomarkers for the prediction of AKI severity. J. Am. Soc. Nephrol. 2015;26(8):2023–2031.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4520172</ArticleId>
            <ArticleId IdType="pubmed">25655065</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ostermann M., Zarbock A., Goldstein S., Kashani K., Macedo E., Murugan R., Bell M., Forni L., Guzzi L., Joannidis M., Kane-Gill S.L., Legrand M., Mehta R., Murray P.T., Pickkers P., Plebani M., Prowle J., Ricci Z., Rimmele T., Rosner M., Shaw A.D., Kellum J.A., Ronco C. Recommendations on acute kidney injury biomarkers from the acute disease quality initiative consensus conference: a consensus statement. JAMA Netw. Open. 2020;3(10)</Citation>
        </Reference>
        <Reference>
          <Citation>Stanski N., Menon S., Goldstein S.L., Basu R.K. Integration of urinary neutrophil gelatinase-associated lipocalin with serum creatinine delineates acute kidney injury phenotypes in critically ill children. J. Crit. Care. 2019;53:1–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31174170</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chawla L.S., Bellomo R., Bihorac A., Goldstein S.L., Siew E.D., Bagshaw S.M., Bittleman D., Cruz D., Endre Z., Fitzgerald R.L., Forni L., Kane-Gill S.L., Hoste E., Koyner J., Liu K.D., Macedo E., Mehta R., Murray P., Nadim M., Ostermann M., Palevsky P.M., Pannu N., Rosner M., Wald R., Zarbock A., Ronco C., Kellum J.A., Acute Disease Quality Initiative W. Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup. Nat. Rev. Nephrol. 2017;13(4):241–257.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28239173</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murray P.T., Mehta R.L., Shaw A., Ronco C., Endre Z., Kellum J.A., Chawla L.S., Cruz D., Ince C., Okusa M.D., workgroup A. Potential use of biomarkers in acute kidney injury: report and summary of recommendations from the 10th Acute Dialysis Quality Initiative consensus conference. Kidney Int. 2014;85(3):513–521.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4198530</ArticleId>
            <ArticleId IdType="pubmed">24107851</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abrahamson M., Dalboge H., Olafsson I., Carlsen S., Grubb A. Efficient production of native, biologically active human cystatin C by Escherichia coli. FEBS Lett. 1988;236(1):14–18.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3042461</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stevens L.A., Schmid C.H., Greene T., Li L., Beck G.J., Joffe M.M., Froissart M., Kusek J.W., Zhang Y.L., Coresh J., Levey A.S. Factors other than glomerular filtration rate affect serum cystatin C levels. Kidney Int. 2009;75(6):652–660.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4557800</ArticleId>
            <ArticleId IdType="pubmed">19119287</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Delgado C., Baweja M., Crews D.C., Eneanya N.D., Gadegbeku C.A., Inker L.A., Mendu M.L., Miller W.G., Moxey-Mims M.M., Roberts G.V., St Peter W.L., Warfield C., Powe N.R. A unifying approach for GFR estimation: recommendations of the NKF-ASN task force on reassessing the inclusion of race in diagnosing kidney disease. Am. J. Kidney Dis. 2022;79(2):268–288 e1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34563581</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schwartz G.J., Schneider M.F., Maier P.S., Moxey-Mims M., Dharnidharka V.R., Warady B.A., Furth S.L., Munoz A. Improved equations estimating GFR in children with chronic kidney disease using an immunonephelometric determination of cystatin C. Kidney Int. 2012;82(4):445–453.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3433576</ArticleId>
            <ArticleId IdType="pubmed">22622496</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kottgen A., Selvin E., Stevens L.A., Levey A.S., Van Lente F., Coresh J. Serum cystatin C in the United States: the third national Health and nutrition examination survey (NHANES III) Am. J. Kidney Dis. 2008;51(3):385–394.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18295054</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koyner J.L., Bennett M.R., Worcester E.M., Ma Q., Raman J., Jeevanandam V., Kasza K.E., O'Connor M.F., Konczal D.J., Trevino S., Devarajan P., Murray P.T. Urinary cystatin C as an early biomarker of acute kidney injury following adult cardiothoracic surgery. Kidney Int. 2008;74(8):1059–1069.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2745082</ArticleId>
            <ArticleId IdType="pubmed">18650797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koyner J.L., Garg A.X., Shlipak M.G., Patel U.D., Sint K., Hong K., Devarajan P., Edelstein C.L., Zappitelli M., Thiessen-Philbrook H., Parikh C.R. A.K.I.C. Translational Research Investigating Biomarker Endpoints in, Urinary cystatin C and acute kidney injury after cardiac surgery. Am. J. Kidney Dis. 2013;61(5):730–738.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3627833</ArticleId>
            <ArticleId IdType="pubmed">23332602</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bellomo R., Ronco C., Kellum J.A., Mehta R.L., Palevsky P., Acute Dialysis Quality Initiative w. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit. Care. 2004;8(4):R204–R212.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC522841</ArticleId>
            <ArticleId IdType="pubmed">15312219</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herget-Rosenthal S., Poppen D., Husing J., Marggraf G., Pietruck F., Jakob H.G., Philipp T., Kribben A. Prognostic value of tubular proteinuria and enzymuria in nonoliguric acute tubular necrosis. Clin. Chem. 2004;50(3):552–558.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14709451</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herget-Rosenthal S., van Wijk J.A., Brocker-Preuss M., Bokenkamp A. Increased urinary cystatin C reflects structural and functional renal tubular impairment independent of glomerular filtration rate. Clin. Biochem. 2007;40(13–14):946–951.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17537416</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nejat M., Pickering J.W., Walker R.J., Westhuyzen J., Shaw G.M., Frampton C.M., Endre Z.H. Urinary cystatin C is diagnostic of acute kidney injury and sepsis, and predicts mortality in the intensive care unit. Crit. Care. 2010;14(3):R85.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2911717</ArticleId>
            <ArticleId IdType="pubmed">20459852</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hassinger A.B., Backer C.L., Lane J.C., Haymond S., Wang D., Wald E.L. Predictive power of serum cystatin C to detect acute kidney injury and pediatric-modified RIFLE class in children undergoing cardiac surgery. Pediatr. Crit. Care Med. 2012;13(4):435–440.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22596066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gharaibeh K.A., Hamadah A.M., El-Zoghby Z.M., Lieske J.C., Larson T.S., Leung N. Cystatin C predicts renal recovery earlier than creatinine among patients with acute kidney injury. Kidney Int. Rep. 2018;3(2):337–342.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5932123</ArticleId>
            <ArticleId IdType="pubmed">29725637</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nejat M., Pickering J.W., Walker R.J., Endre Z.H. Rapid detection of acute kidney injury by plasma cystatin C in the intensive care unit. Nephrol. Dial. Transplant. 2010;25(10):3283–3289.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20350927</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Larki R.A., Jamali B., Meidani M., Mousavi S. Serum cystatin C for evaluation of acute kidney injury in adults treated with colistin. J. Res. Pharm. Pract. 2018;7(4):178–181.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6298137</ArticleId>
            <ArticleId IdType="pubmed">30622984</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soto K., Coelho S., Rodrigues B., Martins H., Frade F., Lopes S., Cunha L., Papoila A.L., Devarajan P. Cystatin C as a marker of acute kidney injury in the emergency department. Clin. J. Am. Soc. Nephrol. 2010;5(10):1745–1754.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2974372</ArticleId>
            <ArticleId IdType="pubmed">20576828</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ebert N., Delanaye P., Shlipak M., Jakob O., Martus P., Bartel J., Gaedeke J., van der Giet M., Schuchardt M., Cavalier E., Schaeffner E. Cystatin C standardization decreases assay variation and improves assessment of glomerular filtration rate. Clin. Chim. Acta. 2016;456:115–121.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26947968</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bargnoux A.S., Pieroni L., Cristol J.P., Kuster N., Delanaye P., Carlier M.C., Fellahi S., Boutten A., Lombard C., Gonzalez-Antuna A., Delatour V., Cavalier E., Societe Francaise de Biologie C. Multicenter evaluation of cystatin C measurement after assay standardization. Clin. Chem. 2017;63(4):833–841.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28188233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>El-Khoury J.M., Hoenig M.P., Jones G.R.D., Lamb E.J., Parikh C.R., Tolan N.V., Wilson F.P. AACC guidance document on laboratory investigation of acute kidney injury. J. Appl. Lab. Med. 2021;6(5):1316–1337.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33973621</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vijayan A., Faubel S., Askenazi D.J., Cerda J., Fissell W.H., Heung M., Humphreys B.D., Koyner J.L., Liu K.D., Mour G., Nolin T.D., Bihorac A., American Society of Nephrology G. Acute kidney injury advisory, clinical use of the urine biomarker [TIMP-2] x [IGFBP7] for acute kidney injury risk assessment. Am. J. Kidney Dis. : Off. J. Natl. Kidney Found. 2016;68(1):19–28.</Citation>
        </Reference>
        <Reference>
          <Citation>Katz N.M., Kellum J.A., Ronco C. Acute kidney stress and prevention of acute kidney injury. Crit. Care Med. 2019;47(7):993–996.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30882483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shankland S.J., Al'Douahji M. Cell cycle regulatory proteins in glomerular disease. Exp. Nephrol. 1999;7(3):207–211.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10352360</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang Q.H., Liu D.W., Long Y., Liu H.Z., Chai W.Z., Wang X.T. Acute renal failure during sepsis: potential role of cell cycle regulation. J. Infect. 2009;58(6):459–464.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19428114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kashani K., Al-Khafaji A., Ardiles T., Artigas A., Bagshaw S.M., Bell M., Bihorac A., Birkhahn R., Cely C.M., Chawla L.S., Davison D.L., Feldkamp T., Forni L.G., Gong M.N., Gunnerson K.J., Haase M., Hackett J., Honore P.M., Hoste E.A., Joannes-Boyau O., Joannidis M., Kim P., Koyner J.L., Laskowitz D.T., Lissauer M.E., Marx G., McCullough P.A., Mullaney S., Ostermann M., Rimmele T., Shapiro N.I., Shaw A.D., Shi J., Sprague A.M., Vincent J.L., Vinsonneau C., Wagner L., Walker M.G., Wilkerson R.G., Zacharowski K., Kellum J.A. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit. Care. 2013;17(1):R25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4057242</ArticleId>
            <ArticleId IdType="pubmed">23388612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bihorac A., Chawla L.S., Shaw A.D., Al-Khafaji A., Davison D.L., Demuth G.E., Fitzgerald R., Gong M.N., Graham D.D., Gunnerson K., Heung M., Jortani S., Kleerup E., Koyner J.L., Krell K., Letourneau J., Lissauer M., Miner J., Nguyen H.B., Ortega L.M., Self W.H., Sellman R., Shi J., Straseski J., Szalados J.E., Wilber S.T., Walker M.G., Wilson J., Wunderink R., Zimmerman J., Kellum J.A. Validation of cell-cycle arrest biomarkers for acute kidney injury using clinical adjudication. Am. J. Respir. Crit. Care Med. 2014;189(8):932–939.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24559465</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoste E.A., McCullough P.A., Kashani K., Chawla L.S., Joannidis M., Shaw A.D., Feldkamp T., Uettwiller-Geiger D.L., McCarthy P., Shi J., Walker M.G., Kellum J.A., Sapphire I. Derivation and validation of cutoffs for clinical use of cell cycle arrest biomarkers. Nephrol. Dial. Transplant. 2014;29(11):2054–2061.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4209880</ArticleId>
            <ArticleId IdType="pubmed">25237065</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gocze I., Jauch D., Gotz M., Kennedy P., Jung B., Zeman F., Gnewuch C., Graf B.M., Gnann W., Banas B., Bein T., Schlitt H.J., Bergler T. Biomarker-guided intervention to prevent acute kidney injury after major surgery: the prospective randomized BigpAK study. Ann. Surg. 2018;267(6):1013–1020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28857811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meersch M., Schmidt C., Hoffmeier A., Van Aken H., Wempe C., Gerss J., Zarbock A. Prevention of cardiac surgery-associated AKI by implementing the KDIGO guidelines in high risk patients identified by biomarkers: the PrevAKI randomized controlled trial. Intensive Care Med. 2017;43(11):1551–1561. doi: 10.1007/s00134-016-4670-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00134-016-4670-3</ArticleId>
            <ArticleId IdType="pmc">PMC5633630</ArticleId>
            <ArticleId IdType="pubmed">28110412</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zarbock A., Kullmar M., Ostermann M., Lucchese G., Baig K., Cennamo A., Rajani R., McCorkell S., Arndt C., Wulf H., Irqsusi M., Monaco F., Di Prima A.L., Garcia Alvarez M., Italiano S., Miralles Bagan J., Kunst G., Nair S., L'Acqua C., Hoste E., Vandenberghe W., Honore P.M., Kellum J.A., Forni L.G., Grieshaber P., Massoth C., Weiss R., Gerss J., Wempe C., Meersch M. Prevention of cardiac surgery-associated acute kidney injury by implementing the KDIGO guidelines in high-risk patients identified by biomarkers: the PrevAKI-multicenter randomized controlled trial. Anesth. Analg. 2021;133(2):292–302.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33684086</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gist K.M., Goldstein S.L., Wrona J., Alten J.A., Basu R.K., Cooper D.S., Soranno D.E., Duplantis J., Altmann C., Gao Z., Faubel S. Kinetics of the cell cycle arrest biomarkers (TIMP-2*IGFBP-7) for prediction of acute kidney injury in infants after cardiac surgery. Pediatr. Nephrol. 2017;32(9):1611–1619. doi: 10.1007/s00467-017-3655-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00467-017-3655-y</ArticleId>
            <ArticleId IdType="pubmed">28382566</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meersch M., Schmidt C., Van Aken H., Rossaint J., Gorlich D., Stege D., Malec E., Januszewska K., Zarbock A. Validation of cell-cycle arrest biomarkers for acute kidney injury after pediatric cardiac surgery. PLoS One. 2014;9(10)</Citation>
        </Reference>
        <Reference>
          <Citation>Meersch M., Schmidt C., Van Aken H., Martens S., Rossaint J., Singbartl K., Gorlich D., Kellum J.A., Zarbock A. Urinary TIMP-2 and IGFBP7 as early biomarkers of acute kidney injury and renal recovery following cardiac surgery. PLoS One. 2014;9(3)</Citation>
        </Reference>
        <Reference>
          <Citation>Chen J., Sun Y., Wang S., Dai X., Huang H., Bai Z., Li X., Wang J., Li Y. The effectiveness of urinary TIMP-2 and IGFBP-7 in predicting acute kidney injury in critically ill neonates. Pediatr. Res. 2020;87(6):1052–1059.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31791043</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chui H., Caldwell J., Yordanova M., Cockovski V., Fredric D., Harel-Sterling M., Haasz M., Al-Ismaili Z., Pizzi M., Ma Q., Devarajan P., Goldstein S.L., Zappitelli M. Tubular injury and cell-cycle arrest biomarkers to predict acute kidney injury in noncritically ill children receiving aminoglycosides. Biomarkers Med. 2020;14(10):879–894.</Citation>
        </Reference>
        <Reference>
          <Citation>Westhoff J.H., Tonshoff B., Waldherr S., Poschl J., Teufel U., Westhoff T.H., Fichtner A. Urinary tissue inhibitor of metalloproteinase-2 (TIMP-2) * insulin-like growth factor-binding protein 7 (IGFBP7) predicts adverse outcome in pediatric acute kidney injury. PLoS One. 2015;10(11)</Citation>
        </Reference>
        <Reference>
          <Citation>Kimmel M., Shi J., Latus J., Wasser C., Kitterer D., Braun N., Alscher M.D. Association of renal stress/damage and filtration biomarkers with subsequent AKI during hospitalization among patients presenting to the emergency department. Clin. J. Am. Soc. Nephrol. 2016;11(6):938–946.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4891754</ArticleId>
            <ArticleId IdType="pubmed">27026519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang H.S., Hur M., Lee K.R., Kim H., Kim H.Y., Kim J.W., Chua M.T., Kuan W.S., Chua H.R., Kitiyakara C., Phattharapornjaroen P., Chittamma A., Werayachankul T., Anandh U., Herath S., Endre Z., Horvath A.R., Antonini P., Di Somma S., Network G. Biomarker rule-in or rule-out in patients with acute diseases for validation of acute kidney injury in the emergency department (BRAVA): a multicenter study evaluating urinary TIMP-2/IGFBP7. Ann. Lab. Med. 2022;42(2):178–187.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8548247</ArticleId>
            <ArticleId IdType="pubmed">34635611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fiorentino M., Xu Z., Smith A., Singbartl K., Palevsky P.M., Chawla L.S., Huang D.T., Yealy D.M., Angus D.C., Kellum J.A., ProCess, Pro G.-A.K.I.I. Serial measurement of cell-cycle arrest biomarkers [TIMP-2]*[IGFBP7] and risk for progression to death, dialysis or severe acute kidney injury in patients with septic Shock. Am. J. Respir. Crit. Care Med. 2020;202(9):1262–1270. doi: 10.1164/rccm.201906-1197OC.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1164/rccm.201906-1197OC</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schanz M., Hoferer A., Shi J., Alscher M.D., Kimmel M. Urinary TIMP2IGFBP7 for the prediction of platinum-induced acute renal injury. Int. J. Nephrol. Renovascular Dis. 2017;10:175–181.</Citation>
        </Reference>
        <Reference>
          <Citation>Toprak Z., Cebeci E., Helvaci S.A., Toprak I.D., Kutlu Y., Sakin A., Tukek T. Cisplatin nephrotoxicity is not detected by urinary cell-cycle arrest biomarkers in lung cancer patients. Int. Urol. Nephrol. 2017;49(6):1041–1047.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28255639</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Daubin D., Cristol J.P., Dupuy A.M., Kuster N., Besnard N., Platon L., Buzancais A., Brunot V., Garnier F., Jonquet O., Klouche K. Urinary biomarkers IGFBP7 and TIMP-2 for the diagnostic assessment of transient and persistent acute kidney injury in critically ill patients. PLoS One. 2017;12(1)</Citation>
        </Reference>
        <Reference>
          <Citation>Bell M., Larsson A., Venge P., Bellomo R., Martensson J. Assessment of cell-cycle arrest biomarkers to predict early and delayed acute kidney injury. Dis. Markers. 2015;2015:158658.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4381987</ArticleId>
            <ArticleId IdType="pubmed">25866432</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kashani K., Cheungpasitporn W., Ronco C. Biomarkers of acute kidney injury: the pathway from discovery to clinical adoption. Clin. Chem. Lab. Med.: CCLM / FESCC. 2017;55(8):1074–1089.</Citation>
        </Reference>
        <Reference>
          <Citation>Martensson J., Bellomo R. The rise and fall of NGAL in acute kidney injury. Blood Purif. 2014;37(4):304–310.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25170751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Charlton J.R., Portilla D., Okusa M.D. A basic science view of acute kidney injury biomarkers, Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association. Eur. Ren. Assoc. 2014;29(7):1301–1311.</Citation>
        </Reference>
        <Reference>
          <Citation>Singer E., Marko L., Paragas N., Barasch J., Dragun D., Muller D.N., Budde K., Schmidt-Ott K.M. Neutrophil gelatinase-associated lipocalin: pathophysiology and clinical applications. Acta Physiol. 2013;207(4):663–672.</Citation>
        </Reference>
        <Reference>
          <Citation>Skrypnyk N.I., Gist K.M., Okamura K., Montford J.R., You Z., Yang H., Moldovan R., Bodoni E., Blaine J.T., Edelstein C.L., Soranno D.E., Kirkbride-Romeo L.A., Griffin B.R., Altmann C., Faubel S. IL-6-mediated hepatocyte production is the primary source of plasma and urine neutrophil gelatinase-associated lipocalin during acute kidney injury. Kidney Int. 2020;97(5):966–979.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8409721</ArticleId>
            <ArticleId IdType="pubmed">32081304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goetz D.H., Holmes M.A., Borregaard N., Bluhm M.E., Raymond K.N., Strong R.K. The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol. Cell. 2002;10(5):1033–1043.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12453412</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grenier F.C., Ali S., Syed H., Workman R., Martens F., Liao M., Wang Y., Wong P.Y. Evaluation of the ARCHITECT urine NGAL assay: assay performance, specimen handling requirements and biological variability. Clin. Biochem. 2010;43(6):615–620.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20026020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cullen M.R., Murray P.T., Fitzgibbon M.C. Establishment of a reference interval for urinary neutrophil gelatinase-associated lipocalin. Ann. Clin. Biochem. 2012;49(Pt 2):190–193.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22323662</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Albert C., Zapf A., Haase M., Rover C., Pickering J.W., Albert A., Bellomo R., Breidthardt T., Camou F., Chen Z., Chocron S., Cruz D., de Geus H.R.H., Devarajan P., Di Somma S., Doi K., Endre Z.H., Garcia-Alvarez M., Hjortrup P.B., Hur M., Karaolanis G., Kavalci C., Kim H., Lentini P., Liebetrau C., Lipcsey M., Martensson J., Muller C., Nanas S., Nickolas T.L., Pipili C., Ronco C., Rosa-Diez G.J., Ralib A., Soto K., Braun-Dullaeus R.C., Heinz J., Haase-Fielitz A. Neutrophil gelatinase-associated lipocalin measured on clinical laboratory platforms for the prediction of acute kidney injury and the associated need for dialysis therapy: a systematic review and meta-analysis. Am. J. Kidney Dis. : Off. J. Natl. Kidney Found. 2020;76(6):826–841. e1.</Citation>
        </Reference>
        <Reference>
          <Citation>Varnell C.D., Jr., Goldstein S.L., Devarajan P., Basu R.K. Impact of near real-time urine neutrophil gelatinase-associated lipocalin assessment on clinical practice. Kidney Int. Rep. 2017;2(6):1243–1249.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5733822</ArticleId>
            <ArticleId IdType="pubmed">29270534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mishra J., Dent C., Tarabishi R., Mitsnefes M.M., Ma Q., Kelly C., Ruff S.M., Zahedi K., Shao M., Bean J., Mori K., Barasch J., Devarajan P. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet. 2005;365(9466):1231–1238.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15811456</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krawczeski C.D., Goldstein S.L., Woo J.G., Wang Y., Piyaphanee N., Ma Q., Bennett M., Devarajan P. Temporal relationship and predictive value of urinary acute kidney injury biomarkers after pediatric cardiopulmonary bypass. J. Am. Coll. Cardiol. 2011;58(22):2301–2309.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3220882</ArticleId>
            <ArticleId IdType="pubmed">22093507</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parikh C.R., Devarajan P., Zappitelli M., Sint K., Thiessen-Philbrook H., Li S., Kim R.W., Koyner J.L., Coca S.G., Edelstein C.L., Shlipak M.G., Garg A.X., Krawczeski C.D. Postoperative biomarkers predict acute kidney injury and poor outcomes after pediatric cardiac surgery. J. Am. Soc. Nephrol. : JASN (J. Am. Soc. Nephrol.) 2011;22(9):1737–1747.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3171944</ArticleId>
            <ArticleId IdType="pubmed">21836147</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Basu R.K., Zappitelli M., Brunner L., Wang Y., Wong H.R., Chawla L.S., Wheeler D.S., Goldstein S.L. Derivation and validation of the renal angina index to improve the prediction of acute kidney injury in critically ill children. Kidney Int. 2014;85(3):659–667.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4659420</ArticleId>
            <ArticleId IdType="pubmed">24048379</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Basu R.K., Kaddourah A., Goldstein S.L., Investigators A.S. Assessment of a renal angina index for prediction of severe acute kidney injury in critically ill children: a multicentre, multinational, prospective observational study. Lancet Child Adolesc. Health. 2018;2(2):112–120.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6053052</ArticleId>
            <ArticleId IdType="pubmed">30035208</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Menon S., Goldstein S.L., Mottes T., Fei L., Kaddourah A., Terrell T., Arnold P., Bennett M.R., Basu R.K. Urinary biomarker incorporation into the renal angina index early in intensive care unit admission optimizes acute kidney injury prediction in critically ill children: a prospective cohort study, Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association. Eur. Ren. Assoc. 2016;31(4):586–594.</Citation>
        </Reference>
        <Reference>
          <Citation>Hanson H.R., Carlisle M.A., Bensman R.S., Byczkowski T., Depinet H., Terrell T.C., Pitner H., Knox R., Goldstein S.L., Basu R.K.  The American journal of emergency medicine; 2020. Early Prediction of Pediatric Acute Kidney Injury from the Emergency Department: A Pilot Study.</Citation>
        </Reference>
        <Reference>
          <Citation>Stanski N.L., Wong H.R., Basu R.K., Cvijanovich N.Z., Fitzgerald J.C., Weiss S.L., Bigham M.T., Jain P.N., Schwarz A., Lutfi R., Nowak J., Allen G.L., Thomas N.J., Grunwell J.R., Quasney M., Haileselassie B., Chawla L.S., Goldstein S.L. Recalibration of the renal angina index for pediatric septic Shock. Kidney Int. Rep. 2021;6(7):1858–1867.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8258591</ArticleId>
            <ArticleId IdType="pubmed">34307980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gist K.M., SooHoo M., Mack E., Ricci Z., Kwiatkowski D.M., Cooper D.S., Krawczeski C.D., Alten J.A., Goldstein S.L., Basu R.K. Modifying the renal angina index for predicting AKI and related adverse outcomes in pediatric heart surgery. World J. Pediatr. Congenital. Heart Surg. 2022;13(2):196–202.</Citation>
        </Reference>
        <Reference>
          <Citation>Stoops C., Stone S., Evans E., Dill L., Henderson T., Griffin R., Goldstein S.L., Coghill C., Askenazi D.J. Baby NINJA (nephrotoxic injury negated by just-in-time action): reduction of nephrotoxic medication-associated acute kidney injury in the neonatal intensive care unit. J. Pediatr. 2019;215:223–228 e6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7393580</ArticleId>
            <ArticleId IdType="pubmed">31761141</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goldstein S.L., Dahale D., Kirkendall E.S., Mottes T., Kaplan H., Muething S., Askenazi D.J., Henderson T., Dill L., Somers M.J.G., Kerr J., Gilarde J., Zaritsky J., Bica V., Brophy P.D., Misurac J., Hackbarth R., Steinke J., Mooney J., Ogrin S., Chadha V., Warady B., Ogden R., Hoebing W., Symons J., Yonekawa K., Menon S., Abrams L., Sutherland S., Weng P., Zhang F., Walsh K. A prospective multi-center quality improvement initiative (NINJA) indicates a reduction in nephrotoxic acute kidney injury in hospitalized children. Kidney Int. 2020;97(3):580–588.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31980139</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goldstein S.L., Krallman K.A., Schmerge A., Dill L., Gerhardt B., Chodaparavu P., Radomsky A., Kirby C., Askenazi D.J. Urinary neutrophil gelatinase-associated lipocalin rules out nephrotoxic acute kidney injury in children. Pediatr. Nephrol. 2021;36(7):1915–1921.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33459927</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Slagle C.L., Goldstein S.L., Gavigan H.W., Rowe J.A., Krallman K.A., Kaplan H.C., Liu C., Ehrlich S.R., Kotagal M., Bondoc A.J., Poindexter B.B. Association between elevated urine neutrophil gelatinase-associated lipocalin and postoperative acute kidney injury in neonates. J. Pediatr. 2021;238:193–201 e2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8551040</ArticleId>
            <ArticleId IdType="pubmed">34371091</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parikh C.R., Devarajan P., Zappitelli M., Sint K., Thiessen-Philbrook H., Li S., Kim R.W., Koyner J.L., Coca S.G., Edelstein C.L., Shlipak M.G., Garg A.X., Krawczeski C.D., Consortium T.-A. Postoperative biomarkers predict acute kidney injury and poor outcomes after pediatric cardiac surgery. J. Am. Soc. Nephrol. : JASN (J. Am. Soc. Nephrol.) 2011;22(9):1737–1747.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3171944</ArticleId>
            <ArticleId IdType="pubmed">21836147</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yilmaz A., Sevketoglu E., Gedikbasi A., Karyagar S., Kiyak A., Mulazimoglu M., Aydogan G., Ozpacaci T., Hatipoglu S. Early prediction of urinary tract infection with urinary neutrophil gelatinase associated lipocalin. Pediatr. Nephrol. 2009;24(12):2387–2392.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19649660</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cai L., Borowiec J., Xu S., Han W., Venge P. Assays of urine levels of HNL/NGAL in patients undergoing cardiac surgery and the impact of antibody configuration on their clinical performances. Clin. Chim. Acta. 2009;403(1–2):121–125.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19361453</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang H., Su M., Yang B., Ren Y., Li L., Zhao D., Huang D., Gao X. The influence of hyperbilirubinemia on indexes of kidney function in neonates. Pediatr. Nephrol. 2021;36(11):3711–3716.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34061255</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
